Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

Table 16 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Belgium

	EQ-5D-3L at 6 months (mean)	EQ-5D-3L at 12 months (mean)	Difference between 12 and 6 months EQ-5D-3L (95% CI)	Effect size (Cohen’s D)^a	n	% reporting 3L score increase
3L-VAS
Improved	0.82	0.84	0.02 (− 0.05 to 0.09)	0.25	6	33
No change	0.80	0.77	− 0.02 (− 0.11 to 0.06)	− 0.12	32	25
Worsened	0.80	0.77	− 0.02 (0.10 to 0.04)	− 0.13	20	20

	EQ-5D-5L at 6 months (mean)	EQ-5D-5L at 12 months (mean)	Difference between 12 and 6 months EQ-5D-5L (95% CI)	Effect size (Cohen’s D)	n	% reporting 5L score increase
5L-VAS
Improved	0.70	0.70	0.00 (− 0.15 to 0.15)	− 0.01	9	33
No change	0.80	0.78	− 0.02 (− 0.07 to 0.01)	− 0.17	29	41
Worsened	0.78	0.74	− 0.03 (− 0.12 to 0.05)	− 0.18	20	30

^aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large

ISSN: 1477-7525